Literature DB >> 23441022

Median-Based Incremental Cost-Effectiveness Ratio (ICER).

Heejung Bang1, Hongwei Zhao.   

Abstract

Cost-effectiveness analysis (CEA) is a type of economic evaluation that examines the costs and health outcomes of alternative strategies and has been extensively applied in health sciences. The incremental cost-effectiveness ratio (ICER), which represents the additional cost of one unit of outcome gained by one strategy compared with another, has become a popular methodology in CEA. Despite its popularity, limited attention has been paid to summary measures other than the mean for summarizing cost as well as effectiveness in the context of CEA. Although some apparent advantages of other central tendency measures such as median for cost data that are often highly skewed are well understood, thus far, the median has rarely been considered in the ICER. In this paper, we propose the median-based ICER, along with inferential procedures, and suggest that mean and median-based ICERs be considered together as complementary tools in CEA for informed decision making, acknowledging the pros and cons of each. If the mean and median-based CEAs are concordant, we may feel reasonably confident about the cost-effectiveness of an intervention, but if they provide different results, our confidence may need to be adjusted accordingly, pending further evidence.

Entities:  

Keywords:  cost-effectiveness analysis; cost-effectiveness plane; mean cost; median cost

Year:  2012        PMID: 23441022      PMCID: PMC3577357          DOI: 10.1080/15598608.2012.695571

Source DB:  PubMed          Journal:  J Stat Theory Pract        ISSN: 1559-8608


  31 in total

1.  Representing uncertainty: the role of cost-effectiveness acceptability curves.

Authors:  E Fenwick; K Claxton; M Sculpher
Journal:  Health Econ       Date:  2001-12       Impact factor: 3.046

2.  On estimating medical cost and incremental cost-effectiveness ratios with censored data.

Authors:  H Zhao; L Tian
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

3.  Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.

Authors:  B J O'Brien; A H Briggs
Journal:  Stat Methods Med Res       Date:  2002-12       Impact factor: 3.021

4.  Median regression with censored cost data.

Authors:  Heejung Bang; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

5.  Why don't Americans use cost-effectiveness analysis?

Authors:  Peter J Neumann
Journal:  Am J Manag Care       Date:  2004-05       Impact factor: 2.229

6.  The CE plane: a graphic representation of cost-effectiveness.

Authors:  W C Black
Journal:  Med Decis Making       Date:  1990 Jul-Sep       Impact factor: 2.583

Review 7.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

Authors:  Scott Ramsey; Richard Willke; Andrew Briggs; Ruth Brown; Martin Buxton; Anita Chawla; John Cook; Henry Glick; Bengt Liljas; Diana Petitti; Shelby Reed
Journal:  Value Health       Date:  2005 Sep-Oct       Impact factor: 5.725

8.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.

Authors:  M A Chaudhary; S C Stearns
Journal:  Stat Med       Date:  1996-07-15       Impact factor: 2.373

9.  The negative side of cost-effectiveness analysis.

Authors:  A A Stinnett; J Mullahy
Journal:  JAMA       Date:  1997-06-25       Impact factor: 56.272

10.  Show me the data.

Authors:  Mike Rossner; Heather Van Epps; Emma Hill
Journal:  J Cell Biol       Date:  2007-12-17       Impact factor: 10.539

View more
  23 in total

1.  The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran.

Authors:  Mohammadreza Amirsadri; Sarah Mousavi; Ali Karimipour
Journal:  Daru       Date:  2019-07-31       Impact factor: 3.117

2.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

3.  Median-based incremental cost-effectiveness ratios with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

Review 4.  Cost-effectiveness of anterior surgical decompression surgery for cervical degenerative disk disease: a systematic review of economic evaluations.

Authors:  V N E Schuermans; A Y J M Smeets; A F M Boselie; O Zarrouk; S M M Hermans; R Droeghaag; I Curfs; S M A A Evers; H van Santbrink
Journal:  Eur Spine J       Date:  2022-02-28       Impact factor: 2.721

5.  Nonparametric inference for time-dependent incremental cost-effectiveness ratios.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Stat Med       Date:  2015-07-27       Impact factor: 2.373

6.  Reducing neuropsychiatric symptoms in persons with dementia and associated burden in family caregivers using tailored activities: Design and methods of a randomized clinical trial.

Authors:  Laura N Gitlin; Catherine Verrier Piersol; Nancy Hodgson; Katherine Marx; David L Roth; Deidre Johnston; Quincy Samus; Laura Pizzi; Eric Jutkowitz; Constantine G Lyketsos
Journal:  Contemp Clin Trials       Date:  2016-06-21       Impact factor: 2.226

7.  Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.

Authors:  Marcos Aurélio Fonseca Magalhães Filho; Pedro Nazareth Aguiar; Milena Brachmans Mascarenhas Neves; Gilberto de Lima Lopes; Auro Del Giglio
Journal:  Einstein (Sao Paulo)       Date:  2022-05-06

8.  Cost-effectiveness of clinical decision support system in improving maternal health care in Ghana.

Authors:  Maxwell Ayindenaba Dalaba; Patricia Akweongo; Raymond Akawire Aborigo; Happiness Pius Saronga; John Williams; Antje Blank; Jens Kaltschmidt; Rainer Sauerborn; Svetla Loukanova
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

9.  Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.

Authors:  Samuel Alan Stewart; Amelia O Clive; Nick A Maskell; Erika Penz
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

10.  Economic Evaluation of Individual School Closure Strategies: The Hong Kong 2009 H1N1 Pandemic.

Authors:  Zoie Shui-Yee Wong; David Goldsman; Kwok-Leung Tsui
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.